永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

未开盘 08-12 15:52:30

0.385

+0.010

+2.67%

最高0.385	最低0.360	成交量16.60万
今开0.360	昨收0.375	日振幅6.67%
总市值2.38亿	流通市值2.38亿	总股本6.18亿
成交额5.99万	换手率0.03%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.385,"timestamp":1786521150373,"preClose":0.375,"halted":0,"volume":166000,"delay":0,"changeRate":0.02666666666666669,"floatShares":618000000,"shares":618000000,"eps":-0.4885455344391959,"marketStatus":"未开盘","change":0.01,"latestTime":"08-12 15:52:30","open":0.36,"high":0.385,"low":0.36,"amount":59930,"amplitude":0.066667,"askPrice":0.39,"askSize":74000,"bidPrice":0.36,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.48156631251863596,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786584600000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.375,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"volumeRatio":2.1957381553874415,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/tweets","defaultTab":"tweets","newsList":[{"id":"2658976570","title":"恒瑞医药两款创新药同日宣布获批临床试验 一季度创新药收入占比超六成","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976570","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658976570?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:05","pubTimestamp":1786529126,"startTime":"0","endTime":"0","summary":"8月11日盘后，恒瑞医药（SH600276，股价54.97元，市值3635.26亿元）连发两则公告，宣布公司及子公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，两款自主研发的创新药获批开展临床试验，研发管线再添新进展。其中一款为针对2型糖尿病的多肽类三靶点激动剂，另一款为针对炎症性肠病的治疗用生物制品，两者在全球范围内均尚无同类药物获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123839273045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123839273045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828474.EUR","BK0060","BMED","IBBQ","LU1997244956.HKD","BK0239","LU2580892862.HKD","LU2328871848.SGD","BK0012","BK0196","LU1820825898.SGD","LU1781817850.SGD","LU2097828714.EUR","LU1997245177.USD","LU1064130708.USD","BK0028","LNGR","LU2543165471.USD","600276","LU1064131003.USD","PSYK","BK1161","LU0405327148.USD","159992","LU1969619763.USD","LU2148510915.USD","IBBJ","LU0359201612.USD","BK0188","06978","LU1580142542.USD","LU0405327494.USD","BK0183","LU2580892789.USD","BK1191","MDTX","LU1023057109.AUD","LU2097828631.EUR","LU1655091616.SGD","MEDX","LU2097828557.USD","LU0359201885.HKD","LU1255011170.USD","LU2495084118.USD","01276","BK1574","LU0359202008.SGD","LU1328615791.USD","LU2097828805.USD","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658097654","title":"创胜集团拟处置杭州相关资产 聚焦创新药主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2658097654","media":"中国财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658097654?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:54","pubTimestamp":1786528465,"startTime":"0","endTime":"0","summary":"近日，创胜集团医药-B（06628.HK）发布公告称，创胜集团全资子公司杭州奕安济世生物药业有限公司（以下简称“奕安济世”）与药明生物旗下杭州明德生物医药技术有限公司签署资产购买协议，拟作价人民币1.9亿元出售杭州医药合同研发生产机构（CDMO）相关资产，包括目标厂房土地使用权、房屋所有权、生产设备、存量业务合约等资产权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123839261530.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123839261530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LNGR","MEDX","IBBQ","06628","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978437","title":"以岭药业(002603.SZ)：化药创新药“LB220-D08缓释片”药物临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978437","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978437?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:00","pubTimestamp":1786525244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，该药物名称：“LB220-D08缓释片”。LB220-D08为公司自主研发的全新小分子化学药物，是公司具有独立知识产权的1类化学新药。本品为靶向FactorB因子的补体抑制剂。通过靶向抑制B因子，本品可选择性抑制旁路途径，阻止C3转化酶的活化，从而抑制C3a、C5a等毒素的生成以及C5转化酶和膜攻击复合物(MAC，C5b-9)的形成，并保持凝集素和经典途径信号通路的正常功能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","MEDX","PSYK","BK1574","IBBJ","BMED","IBBQ","BK0042","06978","MDTX","BK0097","LNGR","BK0239","BK0046","BK1161","002603","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658922703","title":"海思科(002653.SZ)获得创新药HSK60002片药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658922703","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658922703?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:49","pubTimestamp":1786520993,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海思科(002653.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》，经审查，2026年7月受理的HSK60002片符合药品注册的有关要求，同意本品开展临床试验。HSK60002片是公司自主研发的，具有独立知识产权的口服小分子制剂，拟用于炎症性疾病的治疗。临床前研究数据表明，HSK60002在相关动物模型中表现出显著的药效活性，作用机制明确。综合现有结果，HSK60002具备明确的开发价值和良好的转化前景，有望为临床患者提供一种高效、安全的新型治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK0077","BK0028","BK0239","PSYK","BK0033","MDTX","LNGR","BK1161","002653","BK1574","MEDX","BK0188","06978","159992","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658447928","title":"出海提速+中报兑现+AI赋能，创新药板块景气修复延续！T+0恒生创新药ETF华泰柏瑞（520500）年内份额增长77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658447928","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658447928?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:33","pubTimestamp":1786505580,"startTime":"0","endTime":"0","summary":"下半年以来，创新药板块的修复行情持续推进。作为当前A股市场仅有的跟踪恒生创新药指数的ETF，恒生创新药ETF华泰柏瑞今年以来合计“吸金”14.45亿元，助推基金份额与规模分别攀升至22.10亿份、32.30亿元，较年初分别增长77%、67%，流动性优势较突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-12/doc-inimzqcv4064339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ARTY","QTOC","LNGR","AGIX","06978","BK1161","CHAT","159992","BK1574","AIPO","520500","MEDX","IBBQ","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"医药调研热度超越半导体！创新药回调，华宝基金港股通创新药ETF失守半年线！CXO韧性十足，药明系逆市飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658288069?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持，CXO韧性十足，药明生物、药明康德、药明合联逆市飘红，金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿，百济神州跌2%止步6连阳，翰森制药跌逾3%；再鼎医药延续涨势，股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落，现跌1%再失半年线。8月以来，创新药及产业链利好密集，“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSI","VGT","BK4588","CXO","NBDS","BK1515","SOXY","USD","SMH","TECY","MEDX","EIS","CHPY","SSG","SMHU","SOXL","BK4535","LNGR","SMHX","IBBQ","CHPS","159938","SOXQ","FTXL","159316","FWD","BK1574","WX","SOXX","XSD","BK1161","BK4585","MQQQ","FLHK","09939","159992","06978","159582","TEKX","CWC","SOXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658409069","title":"创新药人气股，2分钟直线涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2658409069","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658409069?lang=zh_cn&edition=full","pubTime":"2026-08-12 10:21","pubTimestamp":1786501260,"startTime":"0","endTime":"0","summary":"此前在8月10日，百花医药发布股票交易异常波动公告称，公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归母净利润664.27万元，同比下降67.94%。公司股价短期内波动较大，公司股票目前已累积较大二级市场交易风险，未来存在快速下跌的风险。创新药板块中，誉衡药业涨超9%，万邦医药涨超8%，泓博医药、昆药集团、陇神戎发、美迪西跟涨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-08-12/doc-inimzivt3775229.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-12/doc-inimzivt3775229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","IBBQ","BK1574","06978","159992","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658940465","title":"华泰 | 策略：景气改善的新亮点在必选消费","url":"https://stock-news.laohu8.com/highlight/detail?id=2658940465","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658940465?lang=zh_cn&edition=full","pubTime":"2026-08-12 07:14","pubTimestamp":1786490040,"startTime":"0","endTime":"0","summary":"正文景气改善的新亮点在必选消费7月全行业景气指数小幅回落，与PMI回落相印证；但景气改善的板块增加，必选消费、中游制造、中游材料等板块景气改善幅度居前。涨价链煤炭7月华泰策略煤炭景气指数57.5，较4月爬坡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649860981&idx=2&sn=2e5e4129c862c9dcfc9b28bd80010e70&chksm=89c4e48d885873d25fca78dd362b2891ace8d91743244e1bdecdf97ab1d72915833917c024dd&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["MEDX","BK4204","COPJ","BK1574","06978","BK1161","CATG","BK4535","IQM","BK4585","IBBQ","COPX","BK4588","LNGR","PBOT","COPP","CPER","ICOP","CPXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658028918","title":"8月，真正的机会在这个方向！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658028918","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658028918?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:50","pubTimestamp":1786452609,"startTime":"0","endTime":"0","summary":"眼下的市场，一半火焰，一半海水。短期反弹还是会转化为中长期的反转，是当前的一个核心重点，科技股止跌，但内部分化加剧。创新药等非AI科技则纷纷启动新一轮上涨，但整体增量资金入场积极性较弱，市场又到了关键的窗口期。　　主力资金在科技股与非科技之间加快轮动，这在今天的市场再一次鲜明体现。硬科技中的太极实业、洁美科技等均强势涨停，创新药中的甘李药业、药康生物等均创出新高。8月接下来真正的机会到底在哪里？","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/11/20260811164641.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/11/20260811164641.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260811/32332076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["07266","09086","07568","TTTN","IBBQ","MEDX","XLK","07522","07261","03034","BK1147","03086","LNGR","06978","BK4585","BK1574","BK1161","09834","03455","VGT","02834","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101667152","title":"永泰生物-B(06978)拟于8月21日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1101667152","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101667152?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:45","pubTimestamp":1786452326,"startTime":"0","endTime":"0","summary":"永泰生物製药有限公司（股票代码：06978）8月11日公告称，公司董事会计划于2026年8月21日（星期五）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及相关公告事宜。\n\\n\\n公告显示，公司现任董事会成员包括：主席兼执行董事谭錚；非执行董事杨帆、王瑞华、王东虎、杨昕、刘锐及曹冉；独立非执行董事王英典、吴智杰、彭素玖及张国光。\n\\n\\n公司强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并对其准确性或完整性不作任何声明或保证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992486","title":"海外顶级学术会议密集来袭，国产创新药迎数据披露窗口，创新药ETF易方达（516080）昨日“揽金”1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992486?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:16","pubTimestamp":1786447005,"startTime":"0","endTime":"0","summary":"截至收盘，恒生港股通创新药指数上涨0.3%，中证港股通医药卫生综合指数上涨0.3%，中证创新药产业指数上涨0.5%，中证生物科技主题指数上涨0.5%，沪深300医药卫生指数下跌0.4%。同花顺iFinD数据显示，创新药ETF易方达昨日获1.62亿元资金净流入。业内观点指出，中国创新药在国际舞台上的学术话语权正在不断提升。在2026年的ASCO年会上，中国创新药企累计拿下了94项口头报告，多项核心数据双双刷新历年纪录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026081100032744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["516080","BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399355","title":"杨德龙：科技“六大赛道”有望轮番表现 关注细分行业龙头机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399355","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658399355?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:23","pubTimestamp":1786436580,"startTime":"0","endTime":"0","summary":"去年年初我就提出科技“六大赛道”的观点。现在来看，这六大赛道轮番表现，成为AI时代真正受益的方向，包括芯片半导体、算力算法、人形机器人、商业航天、固态电池、生物医药等。建议大家把握住板块轮动，配置行业龙头股，抓住机会。我已经给大家指明，科技行情没有结束，并给大家提出了六大赛道；现在是行业轮动，大家可以在这六大赛道里面寻找龙头股。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjsy/2026-08-11/doc-inimxrnm7544791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PBOT","BK4585","IQM","WDRN","BK4588","BK1161","UBOT","VGT","LNGR","IBBQ","MEDX","ARTY","ROBT","CHAT","06978","RTOO","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658964054","title":"创新药概念持续走强，我武生物涨近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658964054?lang=zh_cn&edition=full","pubTime":"2026-08-11 13:56","pubTimestamp":1786427794,"startTime":"0","endTime":"0","summary":"8月11日，创新药概念盘中持续走强，我武生物一度涨近4%，触及25.98元/股。中泰证券表示，2026年以来，中国创新药产业逐步进入价值兑现阶段，行业逻辑由过去依赖BD事件催化，转向海外商业化、临床数据兑现及持续收入贡献，近期海外龙头药企财报持续验证中国创新资产价值，MNC对于中国创新药的战略定位逐渐提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081100018659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0028","300357","BK1574","BK1161","159992","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969144","title":"半年报验证创新药景气预期！T+0恒生创新药ETF华泰柏瑞（520500）聚焦产业链复苏机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969144","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969144?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:40","pubTimestamp":1786419600,"startTime":"0","endTime":"0","summary":"支持场内T+0的恒生创新药ETF华泰柏瑞7月以来日均成交额达23.4亿元，相较2026年上半年8.81亿元的日均成交额，资金活跃度显著攀升。交投踊跃之下，恒生创新药ETF华泰柏瑞截至8月10日最新份额、规模分别达22.12亿份、32.19亿元，今年以来产品份额增加76.68%，规模增加66.1%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-11/doc-inimxewr7636555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","IBBQ","520500","159992","MEDX","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","IBBQ","LU1226288170.HKD","LU2328871848.SGD","01548","BK1588","09688","06855","BK1583","LU0880133367.SGD","HK0000320223.HKD","HK0000306685.HKD","LU0315179316.USD","LU1226287875.USD","LNGR","02228","01093","09969","LU2488822045.USD","KURE","IE00BZ08YS42.EUR","LU1152091168.USD","IE00B031HY20.USD","02359","LU1813983027.USD","LU2039709279.SGD","02268","02410","BK1521","LU1993786604.SGD","LU0072913022.USD","IE00BZ08YR35.GBP","BK1500","BK1617","LU0326950275.SGD","LU2125910500.SGD","03692","LU2242644610.SGD","IE00B543WZ88.USD","159992","IE00BZ08YT58.USD","LU1226287792.SGD","06160","BK1576","IE00B5MMRT66.SGD","LU1303224171.USD","LU1951186391.HKD","BK1515","MEDX","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965769","title":"A股三大股指早盘震荡下跌，创新药继续活跃，商业航天陷调整，港股科网股分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965769","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965769?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:10","pubTimestamp":1786414218,"startTime":"0","endTime":"0","summary":"A股创新药、CRO概念延续涨势，百花医药6连板，甘李药业涨停，长春高新、万邦医药、博瑞医药、亚太药业涨幅居前。商业航天概念早盘下挫，中国卫星逼近跌停，超捷股份、斯瑞新材跌超10%，神剑股份、电科蓝天、航天环宇、金风科技跌超7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3779141","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASUP","159982","SPCQ","BK1161","SPCG","SPCI","WARP","LOFF","06978","MARS","VXUS","159992","SPCM","LOFD","BK4564","ASTY","SPCU","IBBQ","WSPC","DIPR","SPCF","KCAI","SPAL","RKX","BK4588","FSPC","LNGR","ELOL","BK1574","MEDX","SPCH","ROKT","SNK","GALX","SSPC","WAR","BK4585","UFO","XSPC","XSHP","ORBX","SPAX","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950174","title":"创新药“中国首发”密集落地 新靶点、新机制、新疗法加速向中国集聚","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950174","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950174?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:42","pubTimestamp":1786405353,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658981293","title":"上海：支持企业研发的创新药、现代中药和高端医疗器械全球注册认证并在当地实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2658981293","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658981293?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:08","pubTimestamp":1786352902,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LGHT","GDOC","PTH","159883","RSPH","159992","IBBQ","MEDX","BK1100","09996","BK1583","MDEV","LNGR","IEIH","AGNG","BK1574","HART","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658019786","title":"上半年创新药BD交易破千亿美元，港股通创新药ETF易方达（159316）标的指数涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658019786","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658019786?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:42","pubTimestamp":1786329734,"startTime":"0","endTime":"0","summary":"今日早盘，创新药板块再度活跃，截至10:17，恒生港股通创新药指数上涨2.9%，成份股中，云顶新耀上涨7.7%，远大医药上涨6.6%。近期，咨询服务机构沙利文在2026生命科学新投资高峰论坛上披露，2026年上半年，中国创新药对外授权交易潜在总额达1100亿美元，交易规模已经提前达到了2025年全年的八成。此外，在全球Top10的BD交易中，中国企业独占8席。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026081000007068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK1161","06978","516080","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658013186","title":"周期无常，创新药核心价值永不褪色","url":"https://stock-news.laohu8.com/highlight/detail?id=2658013186","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658013186?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:29","pubTimestamp":1786328940,"startTime":"0","endTime":"0","summary":"但这种周期性的情绪波动，丝毫不改真正优秀的创新药核心资产所锚定的长期内在价值。在8月这个火热的半年报披露季，创新药产业链的核心优质资产，正以超预期的业绩兑现，有力地论证了创新药赛道不可替代的底层价值。也就是说，一款创新药一旦建立真正的全球范围产品优势，其长期价值将由全球患者需求和国际市场份额共同定义。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-10/doc-inimuvrt2959631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","BK1161","LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0405},{"period":"1month","weight":-0.287},{"period":"3month","weight":-0.5674},{"period":"6month","weight":-0.8514},{"period":"1year","weight":-0.9066},{"period":"ytd","weight":-0.8686}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.022861},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}